




Searching News Database: Abraxis BioScience
HSMN NewsFeed - 17 Nov 2020
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed - 28 Jan 2010
Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
HSMN NewsFeed - 31 Mar 2008
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed - 27 Feb 2008
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
HSMN NewsFeed - 8 Feb 2008
APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
HSMN NewsFeed - 8 Feb 2008
APP Pharmaceuticals Receives FDA Approval for Caffeine Citrate Oral Solution, USP
APP Pharmaceuticals Receives FDA Approval for Caffeine Citrate Oral Solution, USP
HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
HSMN NewsFeed - 17 Jan 2008
APP Pharmaceuticals Receives FDA Approval for Polymyxin B Sulfate for Injection, USP
APP Pharmaceuticals Receives FDA Approval for Polymyxin B Sulfate for Injection, USP
HSMN NewsFeed - 10 Aug 2007
APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
HSMN NewsFeed - 7 Aug 2007
Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial
Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial
HSMN NewsFeed - 6 Aug 2007
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
HSMN NewsFeed - 4 Jul 2007
Circassia Announces the Appointment of Sir Richard Sykes as Chairman of the Board
Circassia Announces the Appointment of Sir Richard Sykes as Chairman of the Board
HSMN NewsFeed - 19 Apr 2007
Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 28 Nov 2006
Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP
Abraxis BioScience Receives FDA Approval for Ampicillin and Sulbactam for Injection, 15g, USP
HSMN NewsFeed - 8 Sep 2006
Abraxis BioScience Names Leadership Team for Its Abraxis Pharmaceutical Products Division
Abraxis BioScience Names Leadership Team for Its Abraxis Pharmaceutical Products Division
HSMN NewsFeed - 25 May 2006
Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives
Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives
Additional items found! 14

Members Archive contains
14 additional stories matching:
Abraxis BioScience
(Password required)
Abraxis BioScience
(Password required)